T-bodies as antiviral agents

Current Topics in Microbiology and Immunology

Volumn 260, Issue , 2001, Pages 271-300

  Bitton, N ^a   Debre, P ^a   Eshhar, Z ^a   Gorochov, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHIMERIC PROTEIN; VIRUS VACCINE;

ANTIBODY RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG SAFETY; GENE TRANSFER; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; HUMORAL IMMUNITY; IMMUNOTHERAPY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

HERPES; HERPESVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0034970480     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-05783-4_14     Document Type: Review

References (229)

1. The immune response to influenza infection
2. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis
3. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus
4. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis
5. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes
6. Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors
7. Constitutive expression of various chemokine genes in human T-cell lines infected with human T-cell leukemia virus type 1: Role of the viral transactivator Tax
8. Neutralizing antiviral B cell responses
9. Induction or prevention of immunopathological disease by cloned cytotoxic T cell lines specific for lymphocytic choriomeningitis virus
10. Chemokines and leukocyte traffic
11. Human chemokines: An update
12. Structural characterization of broadly neutralizing human monoclonal antibodies against the CD4 binding site of HIV-1 gp120
13. Human cytomegalovirus encodes a glycoprotein homologous to MHC class I antigens
14. Human cytomegalovirus down-regulates HLA class I expression by reducing the stability of class I H chains
15. Bispecific antibodies that mediate killing of cells infected with human immunodeficiency virus of any strain
16. Intracellular synthesis of Epstein-Barr virus membrane antigen gp350/220. Inhibitory effect of monensin on its expression
17. Single-chain antigen-binding proteins
18. Characterization of T cell-expressed chimeric receptors with antibody-type specificity for the CD4 binding site of HIV-1 gp120
19. + selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project, Project 90-C-195, January 10, 1992
20. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3
21. Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: Withdrawal of chemokines from the environment of cytomegalovirus-infected cells
22. Human monoclonal antibodies to cytomegalovirus. Characterization and recombinant expression of a glycoprotein-B-specific antibody
23. Adoptive immunotherapy of ovarian carcinoma with bs-mAb-targeted lymphocytes: A multicenter study
24. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
25. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines
26. Gene marking to determine whether autologous marrow infusion restores long-term haematopoiesis in cancer patients
27. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells
28. A complex between the MHC class I homologue encoded by human cytomegalovirus and beta 2 microglobulin
29. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
30. "E3/19K" protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens
31. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
32. Lymphocyte homing and homeostasis
33. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. I. Generation and recognition of virus strains and H-2b mutants
34. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells
35. Loss of serum antibodies to a conformational epitope of HIV-1/gp120 identified by a human monoclonal antibody is associated with disease progression
36. + effectors to kill HIV-1-infected cells
37. Human cytomegalovirus encodes three G protein-coupled receptor homologues
38. Potent antitumour activity of a new class of tumour-specific killer cells
39. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
40. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
41. Exploring how to get at-and eradicate-hidden HIV
42. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes
43. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
44. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein
45. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. Agonist and antagonist profiles of viral chemokines
46. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
47. + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML
48. Cytomegaovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment
49. Fine specificity of monoclonal antibodies directed at human T cell receptor variable regions: Comparison with oligonucleotide-driven amplification for evaluation of V beta expression
50. A promoterless retroviral vector indicates that there are sequences in U3 required for 3′ RNA processing
51. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: Analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses
52. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein
53. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes
54. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS
55. The Kaposi's sarcoma-related herpesvirus (KSHV)-encoded chemokine vMIP-I is a specific agonist for the CC chemokine receptor (CCR)8
56. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
57. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
58. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: Optimal design for T cell activation
59. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors
60. Inhibition of MHC class I antigen presentation by viral proteins
61. HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway
62. Role of the karyopherin pathway in human immunodeficiency virus type 1 nuclear import
63. HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase
64. Human cytomegalovirus open reading frame US28 encodes a functional beta chemokine receptor
65. Cell surface phenotype and human T lymphotropic virus type 1 antigen expression in 12 T cell lines derived from peripheral blood and cerebrospinal fluid of West Indian. Guyanese and African patients with tropical spastic paraparesis
66. Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest
67. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail
68. Generation of human monoclonal antibodies to human immunodeficiency virus
69. Dangerous T-cell amnesia
70. Expression of V beta gene segments by Sezary cells
71. Functional assembly of chimeric T-cell receptor chains
72. Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements
73. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
74. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy
75. Endowing T cells with antibody specificity using chimeric T cell receptors
76. Generation of effector T cells expressing chimeric T cell receptor with antibody type-specificity
77. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity
78. How is the Human Genome Project doing, and what have we learned so far?
79. Survival prognosis of HIV-infected patients
80. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load
81. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice
82. Co-infusion of autologous HIV-1 specific gene modified CD4 and CD8 T cells lead to improved T cell survival and tissue trafficking
83. T-cell gene therapy
84. HIV-specific T cell gene therapy in subjects with undetectable viremia on HAART
85. HIV-specific T cell gene therapy suppresses viral local rebound in subjects on HAART
86. Immune evasion by cytomegalovirus-survival strategies of a highly adapted opportunist
87. Pathogenesis of AIDS lymphomas
88. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of genemodified virus-specific T lymphocytes
89. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
90. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen in human sera
91. Repression of MHC class I gene promoter activity by two-exon Tat of HIV
92. Interleukin-4 receptor-directed cytotoxin therapy of AIDS-associated Kaposi's sarcoma tumors in xenograft model
93. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
94. Neutralizing human antibody specific for human cytomegalovirus in E. coli expression system
95. Inhibition of death receptor signals by cellular FLIP
96. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways
97. Human herpesvirus 6 open reading frame U12 encodes a functional beta-chemokine receptor
98. Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies
99. Herpes simplex virus type 1 renders infected cells resistant to cytotoxic T-lymphocyte-induced apoptosis
100. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
101. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection
102. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design
103. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus
104. Long-term survivors of HIV-1 infection
105. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
106. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency
107. Virus escape from CTL recognition
108. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hematopoietic stem-cell transplantation Blood
109. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions
110. Fusion-competent vaccines: Broad neutralization of primary isolates of HIV
111. The purified myxoma virus gamma interferon receptor homolog M-T7 interacts with the heparin-binding domains of chemokines
112. Use of chemokine receptors by poxviruses
113. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients
114. Understanding the mechanisms of sustained signaling and T cell activation
115. The use of hybrid hybridomas to target human cytotoxic T lymphocytes
116. Phage display of peptide-major histocompatibility complex
117. Virus-triggered immune suppression in mice caused by virus-specific cytotoxic T cells
118. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins
119. Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H
120. Detection of cytomegalovirus genome by in situ hybridization in paraffin embedded endomyocardial biopsy specimens of viral myocarditis
121. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients
122. Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes
123. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma
124. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
125. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
126. Interactions of TCRs with MHC-peptide complexes: A quantitative basis for mechanistic models
127. Mapping and investigation of the role in pathogenesis of the major unique secreted 35-kDa protein of rabbitpox virus
128. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
129. + cytotoxic T-cell responses during chronic viral infection
130. Restricted low-level human antibody responses against Epstein-Barr virus (EBV)-encoded latent membrane protein 1 in a subgroup of patients with EBV-associated diseases
131. Clinical application of retroviral gene transfer in oncology: Results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin
132. Retargeting of human lymphocytes against human ovarian carcinoma cells by bispecific antibodies: From laboratory to clinic
133. Putting muscle to work for gene therapy
134. Active specific immunotherapy of melanoma: Clinical results and correlates
135. Development of a self-inactivating lentivirus vector
136. Transduction of human CD34(+) cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors
137. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1
138. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV
139. A spacer region between the single chain antibody-and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity
140. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
141. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector
142. Monoclonal antibodies to human T-cell receptor variable beta regions
143. Cytoplasmic domains of the interleukin-2 receptor beta and gamma chains mediate the signal for T-cell proliferation
144. Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor
145. A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins
146. Virus-triggered acquired immunodeficiency by cytotoxic T-cell-dependent destruction of antigen-presenting cells and lymph follicle structure
147. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
148. Identification of HIV-1 envelope glycoprotein in the serum of AIDS and ARC patients
149. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition
150. Specific cytolysis of HIV-infected cells by lymphocytes armed with bifunctional antibodies
151. Family of disulphide-linked dimers containing the zeta and eta chains of the T-cell receptor and the gamma chain of Fc receptors
152. Blood transfusion and HTLV-I associated myelopathy
153. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences
154. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
155. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
156. Impact of chimeric immune receptor extracellular protein domains on T cell function
157. Cytomegalovirus encodes a potent alpha chemokine
158. A unique phenotype of skin-associated lymphocytes in humans. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites
159. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
160. Viral strategies of immune evasion
161. Development of HIV vectors for anti-HIV gene therapy
162. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma
163. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo
164. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: A molecular model for latency
165. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody
166. + cytotoxic T lymphocyte responses
167. Monoclonal antibody IF5 (anti-CD20) serotherapy of human B cell lymphomas
168. The influence of antigenic variation on cytotoxic T lymphocyte responses in HIV-1 infection
169. Transduction of nondividing cells using pseudotyped defective high-titer HIV type I particles
170. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
171. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
172. Pathogenesis of cytomegalovirus pneumonia in immunocompromised hosts
173. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
174. + cytotoxic T cell therapy of cytomegalovirus and HIV infection
175. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones
176. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains
177. + T lymphocytes armed with universal T-cell receptors
178. + T cells that react with toxic-shock syndrome toxin-1
179. TCRBV23 specificity of two monoclonal antibodies revealed by a panel of human V beta chains expressed in mouse cells
180. Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain
181. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides
182. Use of genemodified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
183. + T cell responses associated with control of viremia
184. Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
185. Transendothelial chemotaxis of human alpha/beta and gamma/delta T lymphocytes to chemokines
186. Distinct patterns and kinetics of chemokine production regulate dendritic cell function
187. + lymphocytes
188. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures
189. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein
190. Targeting of cytotoxic cells against tumors with heterocrosslinked, bispecific antibodies
191. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization
192. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation
193. Human monoclonal anti-HCMV neutralizing antibody from phage display libraries
194. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome
195. The organization of mature T-cell pools
196. Fas-and tumor necrosis factor-induced apoptosis is inhibited by the poxvirus crmA gene product
197. CrmA, a poxvirus-encoded serpin, inhibits cytotoxic T-lymphocyte-mediated apoptosis
198. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40
199. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes
200. Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells
201. Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes
202. Bispecific antibodies reactive with the multidrug-resistance-related glycoprotein and CD3 induce lysis of multidrug-resistant tumor cells
203. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1
204. Autocrine interferon-beta synthesis for gene therapy of HIV infection: Increased resistance to HIV-1 in lymphocytes from healthy and HIV-infected individuals
205. Blocking of retroviral infection at a step prior to reverse transcription in cells transformed to constitutively express interferon beta
206. Functional analysis of the human cytomegalovirus US28 gene by insertion mutagenesis with the green fluorescent protein gene
207. The multichain interleukin-2 receptor: A target for immunotherapy
208. + lymphocytes can control HIV infection in vitro by suppressing virus replication
209. A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-infected identical twins
210. A phase I/II pilot study of the safety of the adoptive transfer of syngeneic genemodified cytotoxic T lymphocytes in HIV-infected identical twins
211. In vivo persistence of genetically modified. HIV-1 specific syngeneic lymphocytes in HIV-1 discordant identical twins
212. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
213. Neutralization serotypes of human immunodeficiency virus type I field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterization
214. Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, recycle lyric capacity
215. Chimeric ScFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules
216. HIV-1 tat binds TAFII250 and represses TAF11250-dependent transcription of major histocompatibility class I genes
217. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry
218. Lentivirus vectors using human and simian immunodeficiency virus elements
219. Biosynthesis, cleavage, degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160
220. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients
221. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies
222. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain
223. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells
224. Inducible vectors for expression in mammalian cells
225. A retrovirus from human leukemia cell lines: Its isolation, characterization, and implication in human adult T-cell leukemia (ATL)
226. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells
227. Lysis of cells infected with HIV-1 by human lymphocytes targeted with monoclonal antibody heteroconjugates
228. Human immunodeficiency virus type I Nef protein sensitizes CD4(+) T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway
229. T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS